Drug Profile
Metablok - Arch Biopartners
Alternative Names: LSALT peptide; MetaBlokLatest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator Arch Biopartners; University of Calgary
- Developer Arch Biopartners; Sunnybrook Health Sciences Centre; University of Calgary
- Class Peptides; Small molecules
- Mechanism of Action Dipeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acute kidney injury; COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- No development reported Cancer metastases; Sepsis
Most Recent Events
- 15 Mar 2024 Arch Biopartners initiates enrollment in phase II CS-AKI trial for Acute kidney injury (Prevention) in Canada (IV, Injection)
- 08 Mar 2024 Arch Biopartners initiates enrollment in a phase II CS-AKI trial for Acute kidney injury (Prevention) in Turkey (IV, Injection) (NCT05879432)
- 10 Jan 2024 Arch Biopartners plans a phase II trial for Acute kidney injury (Prevention) in USA, Canada and Turkey (IV, Injection) in February 2024 (NCT05879432)